Topics

Russian biotechnology company BIOCAD announced plans to enter the EU market

19:00 EST 6 Nov 2019 | AAAS

(BIOCAD) During the 30th anniversary CPhI Worldwide exhibition, at a large-scale international venue that brought together more than 60,000 people from all over the world, BIOCAD introduced 2 new original drugs based on monoclonal antibodies -- an interleukin-17 inhibitor (inn -- netakimab) and a PD-1 inhibitor (inn -- progolimab). Also at the CPhI BIOCAD publicly announced plans to introduce netakimab and prololimab to the European market and start of the clinical trials in Europe.

Original Article: Russian biotechnology company BIOCAD announced plans to enter the EU market

NEXT ARTICLE

More From BioPortfolio on "Russian biotechnology company BIOCAD announced plans to enter the EU market"

Quick Search

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...